How Pham was paid
$1.2M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Quang X. PhamChief Executive Officer | $708,750 | $407,531 | $93,300 | $13,800 | $1,223,381 |
| Matthew SzotChief Financial Officer | $435,850 | $263,126 | $155,503 | $13,800 | $868,279 |
| Jeffrey ColeChief Operating Officer | $363,721 | $160,380 | $154,950 | $47,250 | $726,301 |
What changed and why
- $1.2M$1,223,381 was CEO Quang X. Pham’s total compensation for 2024, compared with $967,000 in 2023.
- $408K$407,531 in 2024 bonuses were accrued by year-end and paid during the first quarter of 2025.
- $93,300$93,300 was the CEO’s 2024 option award value; no stock award was reported.
- $47,250$47,250 was COO Jeffrey Cole’s other compensation, including $33,750 in pre-appointment consulting fees.
- 50%50% of base salary was the annual target bonus opportunity for the CEO and CFO.
- 40%40% of base salary was the annual target bonus opportunity for the COO.
Other Cadrenal Therapeutics proxy statements
- 2026 proxy statement
Quang X. Pham paid $1.9M (+56% on the year).
Filed Aug 03, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.